APC Anti-Mouse CD273 (B7-DC, PD-L2) Antibody

Product Details


CloneTY25
ApplicationFlow Cytometry
ReactivityMouse
FormatAPC
Target NameCD273, PD-L2, PDL2, B7DC
IsotypeRat IgG2a
Antibody TypeMonoclonal
Regulatory StatusRUO
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein Concentration0.2 mg/mL
Storage & HandlingThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended UsageFor flow cytometric staining, it is recommended to use less than 0.2 µg of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. APC has an excitation max at 650 nm and an emission max at 660 nm.
Excitation LaserRed Laser (633 nm)
See All FormatsClone TY25

Background Information


Mouse CD273, also known as programmed death-ligand 2 (PD-L2) or B7-DC, is an immune checkpoint ligand encoded by the Pdcd1lg2 gene. It is primarily expressed on antigen-presenting cells, including dendritic cells and macrophages, and can be induced by inflammatory and Th2-associated cytokines. CD273 plays an important role in regulating T-cell responses and maintaining immune tolerance. Through interaction with its receptors, it can suppress T-cell proliferation and inflammatory cytokine production, although its effects can vary depending on the cellular and tissue context.

Mouse CD273 is a type I transmembrane glycoprotein belonging to the B7 family. Its extracellular region contains an N-terminal immunoglobulin variable (IgV)-like domain followed by an IgC-like domain, a transmembrane segment, and a very short cytoplasmic tail. Notably, mouse and rat PD-L2 have only approximately four amino acids in the cytoplasmic region, whereas human PD-L2 contains a substantially longer cytoplasmic domain. The extracellular IgV domain forms the principal binding interface with its receptors.


The best-characterized ligand/receptor interaction is with programmed cell death protein 1 (PD-1/CD279) on activated T cells. PD-L2 binds PD-1 with higher affinity than PD-L1 and delivers inhibitory signals that limit T-cell activation. CD273 also binds repulsive guidance molecule B (RGMb), a GPI-anchored protein expressed on several immune-cell populations. The PD-L2–RGMb pathway has been implicated particularly in respiratory immune tolerance and regulation of tissue-specific immune responses.


CD273 has been implicated in cancer, allergy, asthma, chronic inflammation, and infectious disease through its ability to regulate immune activation. In mouse tumor models, PD-L2–RGMb signaling can contribute to resistance to PD-1/PD-L1 checkpoint blockade. Therapeutically, CD273 is therefore being investigated as an additional immune-checkpoint target. Blocking PD-L2 or the PD-L2–RGMb interaction can enhance antitumor immunity in preclinical models, particularly when combined with PD-1 or PD-L1 inhibitors. Conversely, enhancing PD-L2 signaling may have potential for treating excessive inflammatory or autoimmune responses by promoting immune tolerance.

Isotype Control


APC/Cyanine7 Rat IgG2a Isotype Control

Data Sheets


APC Anti-Mouse CD273 (B7-DC, PD-L2) Antibody TDS

Related Protocols


Flow Cytometry Protocol


Have a product or application question? Consult our FAQs or contact us.